Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Baylor College of Medicine
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02287311CT.gov Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell And NK-Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mabel Ctls (this asset) | Baylor College of Medicine | P1 | CC · 43 |
| Cyclophosphamide | New York Medical College | P3 | BBB |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Cyclosporin A | Medical College of Wisconsin | P3 | B |
| Equine Atg | Masonic Cancer Center, University of Minnesota | P2 | B |
| Umbilical Cord Blood Mononuclear Cells | Masonic Cancer Center, University of Minnesota | P2 | B |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | B |
| Dexasone | National Cancer Institute (NCI) | P1 | CCC |
| Lenalidomide | National Cancer Institute (NCI) | P1 | CCC |
+18 more in the T-Cell And NK-Cell Neoplasm cohort
Other indications for Mabel Ctls
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P1 | CC · 43 |
| Immunodeficiency 32B | — | P1 | CC · 43 |
| Smooth Muscle Tumor | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mabel Ctls in T-Cell And NK-Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mabel-ctls-t-cell-and-nk-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →